BNBX
BNB Plus Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.30
P/S
0.40
EV/EBITDA
0.06
DCF Value
$-46.57
FCF Yield
-1858.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
23.1%
Operating Margin
-1298.1%
Net Margin
-1515.9%
ROE
-320.3%
ROA
-150.3%
ROIC
-140.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $565.4K | $-18.6M | $-2.08 |
| Q4 2025 | $199.4K | $-5.3M | $-3.17 |
| FY 2025 | $2.1M | $-15.2M | $-134.23 |
| Q3 2025 | $304.4K | $-3.9M | $-34.00 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.70
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.